Clear Search sequence regions

  • adult (2)
  • antibodies (3)
  • child (1)
  • children (3)
  • humans (1)
  • phase (1)
  • research (1)
  • therapies (1)
  • world health (1)
  • Sizes of these terms reflect their relevance to your search.

    Lymphomas are the third most common malignancy in childhood. Cure rates are high but have reached a plateau. Therefore new treatment modalities should be developed. Antibody therapy is a successful new treatment option in adult lymphoma. However, none of the therapeutic antibodies available for adults with cancer have been approved for treatment of paediatric lymphoma. To assess the efficacy of antibody therapy for childhood lymphoma in terms of survival, response and relapse rates, compared with therapy not including antibody treatment. To assess quality of life and the occurrence of adverse effects caused by antibody therapy treatment in children compared with therapy not including antibody treatment. We searched the Cochrane Central Register of Controlled Trials (CENTRAL, 2014, Issue 10), MEDLINE in PubMed (from 1945 to October 2014), EMBASE in (from 1980 to October 2014) and reference lists of relevant articles. Furthermore, we searched conference proceedings abstracts of SIOP, ASCO and ASH for studies from 2009 to 2013), and the World Health Organization (WHO) ICTRP portal and for ongoing trials. Randomised controlled trials and controlled clinical trials comparing conventional therapy with antibody therapy in children with lymphoma. Two authors independently performed the study selection. We found no studies meeting the inclusion criteria of the review. At this moment, it is not possible to draw evidence-based conclusions regarding clinical practice. Phase I and II studies show a positive effect of using antibody therapy in childhood lymphoma. Further research is needed to evaluate and implement antibody therapy for paediatric lymphoma.


    Verena de Zwart, Samantha C Gouw, Friederike A G Meyer-Wentrup. Antibody therapies for lymphoma in children. The Cochrane database of systematic reviews. 2016(1):CD011181

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 26784573

    View Full Text